AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer s Disease and Intermediate Amyloid (A3 Trial)

10064AHEAD3-45Open (affiliates only)AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer s Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer s Disease and Intermediate Amyloid (A3 Trial)NCT04468659Industrial; InstitutionalAdultTreatmentIIIOtherTurner, RaymondGeorgetown University Medical Center : Emma Brennan; Lombardi Comprehensive Cancer Center : Emma BrennanGUMC Neurology14583Emma BrennanEmma Brennaneb1321@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>